论文部分内容阅读
目的探讨ERCC1 codon118基因表达对预测三代含铂方案治疗晚期非小细胞肺癌疗效的影响。方法对240例晚期非小细胞肺癌患者进行ERCC1 codon118基因多样性检测,并对各基因型对三代含铂方案治疗晚期非小细胞肺癌疗效进行比较。结果 C/C型组与C/T型组+T/T型组患者的肿瘤分化程度、临床分期、肿瘤大小、血管侵犯等基本资料无明显的相关性(P>0.05)。C/C型组患者的无进展生存时间为(13.2±5.4)个月,生存时间为(25.4±4.3)个月,1年、2年和3年生存率分别为62.9%、23.5%和14.4%;C/T型+T/T型组患者无进展生存时间和生存时间分别为(6.2±4.3)个月和(10.5±3.2)个月,其1、2和3年生存率分别为26.9%、8.3%和1.9%。结论ERCC1 codon118基因表达可能与预测三代含铂方案治疗晚期非小细胞肺癌敏感性有关。
Objective To investigate the effect of ERCC1 codon118 gene expression on the prognosis of advanced non-small cell lung cancer (NSCLC) treated with third-generation platinum-containing regimen. Methods The genetic diversity of ERCC1 codon118 gene in 240 patients with advanced non-small cell lung cancer (NSCLC) was examined. The efficacy of three generations of platinum-containing regimen in the treatment of advanced non-small cell lung cancer was compared. Results There was no significant correlation between C / C type and C / T type + T / T type of tumor differentiation, clinical stage, tumor size, vascular invasion and other basic data (P> 0.05). Patients in C / C group had a progression-free survival time of (13.2 ± 5.4) months and a mean survival time of (25.4 ± 4.3) months, and their 1-, 2- and 3-year survival rates were 62.9%, 23.5% and 14.4 %. The progression-free survival time and survival time of patients in C / T + T / T group were (6.2 ± 4.3) months and (10.5 ± 3.2) months respectively, and the 1-, 2-, and 3-year survival rates were 26.9 %, 8.3% and 1.9%. Conclusion The expression of ERCC1 codon118 gene may be related to the prediction of the sensitivity of third-generation platinum-containing regimen in the treatment of advanced non-small cell lung cancer.